1
项与 CD22-CART(Zhujiang Hospital of Southern Medical University) 相关的临床试验Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients. CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19-negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.
100 项与 CD22-CART(Zhujiang Hospital of Southern Medical University) 相关的临床结果
100 项与 CD22-CART(Zhujiang Hospital of Southern Medical University) 相关的转化医学
100 项与 CD22-CART(Zhujiang Hospital of Southern Medical University) 相关的专利(医药)
100 项与 CD22-CART(Zhujiang Hospital of Southern Medical University) 相关的药物交易